Dihydroartemisinin inhibits the tumorigenesis and invasion of gastric cancer by regulating STAT1/KDR/MMP9 and P53/BCL2L1/CASP3/7 pathways
- 1 February 2021
- journal article
- research article
- Published by Elsevier in Pathology - Research and Practice
- Vol. 218, 153318
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
This publication has 38 references indexed in Scilit:
- Novel function of STAT1 in breast cancerOncoImmunology, 2013
- Design, Synthesis and Evaluation of the Antibacterial Enhancement Activities of Amino Dihydroartemisinin DerivativesMolecules, 2013
- Tumor Suppression by p53: Fall of the Triumvirate?Cell, 2012
- Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-κB pathwayCancer Chemotherapy and Pharmacology, 2011
- Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignanciesBMC Cancer, 2010
- The anti-cancer activity of dihydroartemisinin is associated with induction of iron-dependent endoplasmic reticulum stress in colorectal carcinoma HCT116 cellsInvestigational New Drugs, 2010
- Tumor-promoting role of signal transducer and activator of transcription (Stat)1 in late-stage melanoma growthClinical & Experimental Metastasis, 2010
- The first 30 years of p53: growing ever more complexNature Reviews Cancer, 2009
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- Over-expression ofbcl-xL gene in human gastric adenomas and carcinomasInternational Journal of Cancer, 1996